| Drug Type Antibody drug conjugate (ADC) | 
| Synonyms- | 
| Target | 
| Action modulators, inhibitors | 
| Mechanism CD45 modulators(Leukocyte common antigen modulators), c-Kit inhibitors(Stem cell growth factor receptor inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 

| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Genetic Diseases, Inborn | Preclinical | United States  | 30 Nov 2022 | |
| Genetic Diseases, Inborn | Preclinical | Germany  | 30 Nov 2022 | |
| Hematologic Neoplasms | Preclinical | United States  | 30 Nov 2022 | |
| Hematologic Neoplasms | Preclinical | Germany  | 30 Nov 2022 | 






